Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
BioNTech indicates the acquisition will add production capacity in support of U.S. clinical trials.
With billions of dollars at stake in potential legal liabilities, the life sciences giant is exploring a possible solution – bankruptcy of a sort.
Medtech company HeartFlow is heading to the New York Stock Exchange through a merger with special purpose acquisition company, Longview Acquisition Corp. II.
Prenetics, which is a diagnostics and genetics testing company, will merge with Artisan Acquisition, a SPAC company backed by Adrian Cheng, chief executive officer of Hong Kong’s New World Development.
No specific financial details were disclosed other than to say the $1 billion figure was linked to various development and commercial milestones.
Novo Nordisk will take over Prothena’s wholly-owned subsidiary and gain full global intellectual property rights and other related rights for the latter’s ATTR amyloidosis business and pipeline.
The 2021 IPO stampede continues with five more companies aiming to trade on a stock exchange.
Philip Morris will acquire Vectura to gain access to its inhaled drug formulas to bolster its Beyond Nicotine strategy.
The move by the 15 states’ attorneys general comes about a month ahead of a court hearing set for Aug. 5.